vs
ADMA BIOLOGICS, INC.（ADMA）与Doximity, Inc.（DOCS）财务数据对比。点击上方公司名可切换其他公司
Doximity, Inc.的季度营收约是ADMA BIOLOGICS, INC.的1.3倍（$185.1M vs $139.2M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs 33.3%，领先2.2%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 9.8%），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 25.2%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
ADMA vs DOCS — 直观对比
营收规模更大
DOCS
是对方的1.3倍
$139.2M
营收增速更快
ADMA
高出8.6%
9.8%
净利率更高
ADMA
高出2.2%
33.3%
两年增速更快
ADMA
近两年复合增速
25.2%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $185.1M |
| 净利润 | $49.4M | $61.6M |
| 毛利率 | 63.8% | 89.9% |
| 营业利润率 | 45.1% | 38.9% |
| 净利率 | 35.5% | 33.3% |
| 营收同比 | 18.4% | 9.8% |
| 净利润同比 | -55.9% | -18.1% |
| 每股收益（稀释后） | $0.20 | $0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMADOCS
| Q4 25 | $139.2M | $185.1M | ||
| Q3 25 | $134.2M | $168.5M | ||
| Q2 25 | $122.0M | $145.9M | ||
| Q1 25 | $114.8M | $138.3M | ||
| Q4 24 | $117.5M | $168.6M | ||
| Q3 24 | $119.8M | $136.8M | ||
| Q2 24 | $107.2M | $126.7M | ||
| Q1 24 | $81.9M | $118.1M |
净利润ADMADOCS
| Q4 25 | $49.4M | $61.6M | ||
| Q3 25 | $36.4M | $62.1M | ||
| Q2 25 | $34.2M | $53.3M | ||
| Q1 25 | $26.9M | $62.5M | ||
| Q4 24 | $111.9M | $75.2M | ||
| Q3 24 | $35.9M | $44.2M | ||
| Q2 24 | $32.1M | $41.4M | ||
| Q1 24 | $17.8M | $40.6M |
毛利率ADMADOCS
| Q4 25 | 63.8% | 89.9% | ||
| Q3 25 | 56.3% | 90.3% | ||
| Q2 25 | 55.1% | 89.2% | ||
| Q1 25 | 53.2% | 89.5% | ||
| Q4 24 | 53.9% | 91.6% | ||
| Q3 24 | 49.8% | 90.0% | ||
| Q2 24 | 53.6% | 89.3% | ||
| Q1 24 | 47.8% | 89.4% |
营业利润率ADMADOCS
| Q4 25 | 45.1% | 38.9% | ||
| Q3 25 | 38.0% | 37.8% | ||
| Q2 25 | 35.1% | 37.4% | ||
| Q1 25 | 30.4% | 35.2% | ||
| Q4 24 | 32.6% | 47.4% | ||
| Q3 24 | 33.1% | 38.8% | ||
| Q2 24 | 36.6% | 36.4% | ||
| Q1 24 | 26.7% | 35.5% |
净利率ADMADOCS
| Q4 25 | 35.5% | 33.3% | ||
| Q3 25 | 27.1% | 36.8% | ||
| Q2 25 | 28.1% | 36.5% | ||
| Q1 25 | 23.4% | 45.2% | ||
| Q4 24 | 95.2% | 44.6% | ||
| Q3 24 | 30.0% | 32.3% | ||
| Q2 24 | 29.9% | 32.7% | ||
| Q1 24 | 21.7% | 34.4% |
每股收益（稀释后）ADMADOCS
| Q4 25 | $0.20 | $0.31 | ||
| Q3 25 | $0.15 | $0.31 | ||
| Q2 25 | $0.14 | $0.27 | ||
| Q1 25 | $0.11 | $0.31 | ||
| Q4 24 | $0.45 | $0.37 | ||
| Q3 24 | $0.15 | $0.22 | ||
| Q2 24 | $0.13 | $0.21 | ||
| Q1 24 | $0.08 | $0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $64.8M |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $979.3M |
| 总资产 | $624.2M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMADOCS
| Q4 25 | $87.6M | $64.8M | ||
| Q3 25 | $61.4M | $169.2M | ||
| Q2 25 | $90.3M | $137.3M | ||
| Q1 25 | $71.6M | $209.6M | ||
| Q4 24 | $103.1M | $165.3M | ||
| Q3 24 | $86.7M | $184.2M | ||
| Q2 24 | $88.2M | $111.4M | ||
| Q1 24 | $45.3M | $96.8M |
总债务ADMADOCS
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADMADOCS
| Q4 25 | $477.3M | $979.3M | ||
| Q3 25 | $431.2M | $1.1B | ||
| Q2 25 | $398.3M | $1.0B | ||
| Q1 25 | $373.4M | $1.1B | ||
| Q4 24 | $349.0M | $1.0B | ||
| Q3 24 | $231.9M | $961.2M | ||
| Q2 24 | $188.3M | $913.6M | ||
| Q1 24 | $153.7M | $901.4M |
总资产ADMADOCS
| Q4 25 | $624.2M | $1.2B | ||
| Q3 25 | $568.7M | $1.3B | ||
| Q2 25 | $558.4M | $1.2B | ||
| Q1 25 | $510.6M | $1.3B | ||
| Q4 24 | $488.7M | $1.2B | ||
| Q3 24 | $390.6M | $1.1B | ||
| Q2 24 | $376.4M | $1.1B | ||
| Q1 24 | $350.9M | $1.1B |
负债/权益比ADMADOCS
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $60.9M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | — |
| 自由现金流率自由现金流/营收 | 24.8% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 0.72× | 0.99× |
| 过去12个月自由现金流最近4个季度 | $27.8M | — |
8季度趋势，按日历期对齐
经营现金流ADMADOCS
| Q4 25 | $35.6M | $60.9M | ||
| Q3 25 | $13.3M | $93.9M | ||
| Q2 25 | $21.1M | $62.1M | ||
| Q1 25 | $-19.7M | $98.5M | ||
| Q4 24 | $50.2M | $65.2M | ||
| Q3 24 | $25.0M | $68.3M | ||
| Q2 24 | $45.6M | $41.2M | ||
| Q1 24 | $-2.2M | $63.9M |
自由现金流ADMADOCS
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | — | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $-4.6M | — |
自由现金流率ADMADOCS
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | -5.6% | — |
资本支出强度ADMADOCS
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 4.1% | 0.0% | ||
| Q4 24 | 2.3% | 0.0% | ||
| Q3 24 | 0.9% | 0.0% | ||
| Q2 24 | 1.9% | 0.0% | ||
| Q1 24 | 2.9% | 0.0% |
现金转化率ADMADOCS
| Q4 25 | 0.72× | 0.99× | ||
| Q3 25 | 0.36× | 1.51× | ||
| Q2 25 | 0.62× | 1.16× | ||
| Q1 25 | -0.73× | 1.58× | ||
| Q4 24 | 0.45× | 0.87× | ||
| Q3 24 | 0.70× | 1.55× | ||
| Q2 24 | 1.42× | 1.00× | ||
| Q1 24 | -0.12× | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
